Monday, February 6, 2017
310 Kelly Hall @ 1:30pm
Dr. Young Shik Shin
Chief Science Officer
Heterogeneity in human disease, especially in cancer, is gaining interest to design more effective therapeutic strategies as well as to understand fundamental biology more in depth. The needs for capturing and analyzing the heterogeneous states of a biological specimen require the development of novel technologies for quantitative and sensitive measurements of cancer specimen with a higher resolution. Over the past few years, we have developed a microfluidic platform called the Single Cell Barcode Chip (SCBC) that permits cytoplasmic, membrane, and/or secreted functional proteins to be quantitatively assayed from individual cells in a multiparameter manner. I will discuss the clinical potential of this technology in suggesting effective single or combination therapies for individual glioblastoma (GBM) patients, based on our recent study on mice and patient-derived GBM tissue analysis. I will also discuss our recent development of a microfluidics-based Positron Emission Tomography (PET) device with which we can measure metabolic activity of single cells under various drug treatment conditions with kinetic information. This platform can provide information on how individual cells react to specific treatment conditions within short time frame (from 30 min to several hours). Measuring heterogeneous metabolic responses at single cell level has the potential to guide clinicians to effectively evaluate drug candidates at early time points for individual patients.
Dr. Young Shik Shin received B.S. and M.S. degrees in Mechanical Engineering from Seoul National University in 2002 and 2004, respectively and Ph.D. degree in Bioengineering from California Institute of Technology in 2011. From 2011 to 2013, he was a joint postdoctoral fellow at Caltech and UCLA under the supervision of Dr. James Heath (Caltech) and Dr. Paul Mischel (UCLA, currently UCSD). Dr. Shin initiated and managed the UCLA/Caltech Translational Medicine Lab (TML) within the Department of Molecular and Medical Pharmacology (DMMP) in the David Geffen School of Medicine at UCLA from 2013 to 2015. Currently, Dr. Shin serves as Chief Science Officer at NanoIVD, Inc, a medical device startup for cancer detection and monitoring.